Home >   Products   >  Advanced Search

Medroxyprogesterone Acetate
(CAS RN:71-58-9 Product Number:M1964)


Medroxyprogesterone Acetate
Synonym 17α-Acetoxy-6α-methylprogesterone
Synonym 17α-Hydroxy-6α-methyl-4-pregnene-3,20-dione 17-Acetate
Synonym Medroxyprogesterone 17-Acetate

General Information

Product Number M1964

* Items available from stock in Japan will be delivered in 10 business days.
* Please contact us if you need further information.
(Sales Dept Tel: +44 1865 78 45 60 E-mail: Sales-UK@TCIchemicals.com)
* To send your quote request for bulk quantities, please click on the “Request Bulk Quotation” button. Please note that for some of our products we cannot offer bulk quantities.
* TCI frequently reviews storage conditions to optimize them. Please note that the latest information on the storage temperature for the products is described on our website.

Purity/Analysis Method >93.0%(GC)
Storage Temperature
M.F. / M.W. C24H34O4=386.53
CAS RN 71-58-9
Related CAS RN
MDL Number MFCD00010483
Packaging and Container
  • Product Details
  • Safety & Regulations


Purity(GC) min. 93.0 %
Melting point 203.0 to 209.0 deg-C
Specific rotation [a]20/D +45.0 to +51.0 deg(C=1, Dioxane)


Beilstein 8(4)2212
Reaxys-RN 2066112
PubChem SID 87560200
RTECS# TU5010000
EC Number 200-757-9


Signal Word Warning
Hazard Statements
  • H351
  • :Suspected of causing cancer.
Precautionary Statements
  • P201
  • :Obtain special instructions before use.
  • P202
  • :Do not handle until all safety precautions have been read and understood.
  • P280
  • :Wear protective gloves, protective clothing, face protection.
  • P308+P313
  • :IF exposed or concerned: Get medical advice or attention.
  • P405
  • :Store locked up.
  • P501
  • :Dispose of contents/container through a waste management company authorized by the local government.

Transport Information

HS Number 2937290000


Medroxyprogesterone acetate: Semi-Synthetic Progestational Agent

Medroxyprogesterone acetate (MPA) and megestrol acetate [M1949], semi-synthetic progestational agents, are effective hormonal treatments for metastatic breast cancer in postmenopausal women. The antineoplastic effect may result from inhibition of pituitary gonadotropin production and resultant decrease in estrogen secretion. In addition, MPA has the pregnancy maintaining effect and the anti-estrogen effect. (The product is for research purpose only.)


Page Top